The primary function of the Protocol Review and Monitoring System is to ensure that all human subjects research is of the highest scientific merit and proceeds at an optimal pace. Over the past 5 years, 934 faculty members participating in human subjects research utilized the PRMS, and 273 new interventional protocols were reviewed by the PRMS in the last year. The PRMS is supported by 32 staff members under the direction of Dr. Aman Buzdar, Vice President for Clinical Research Administration. The core function of the PRMS is to provide a mechanism to ensure adequate internal oversight of the scientific and research aspects of all institutional clinical trials through a rigorous review of the scientific merit, progress, and priorities of the clinical research protocols conducted by the faculty. This function is coordinated by the PRMS as a single source of service, support and oversight The PRMS is made up of several subcommittees (described below) that are designated to provide scientific review and approval for new research protocols, as well as to monitor the progress of the ongoing trials. Importantly, the increasingly complex regulatory requirements and oversight activities have resulted in increased institutional staffing commitments and prompted provision of several new or expanded services, as described in greater detail in this application. During the last grant year, the funds used to support the PRMS function were $240,152 (8%) from the Cancer Center Support Grant (CCSG), $110,000 (4%) from IRB fees, and $2,540,868 (88%) from the institution. It is projected that in the next award cycle, the funds used to support the PRMS function will be $249,758 provided by the CCSG (9%), $110,000 from IRB fees (4%), and $2,406,755 (87%) from the institution. The PRMS consists of four Clinical Research Committees (CRCs) and one Psychosocial Behavioral Health Services Research Committee (PBHSRC) that review protocols for scientific merit. The Chairs of these committees are also members of the Electronic Protocol Accrual Auditing Committee (ePAAC) that selects and monitors all institutional protocols that are identified as slow-accruing. Eight hundred and one protocols were reviewed by ePAAC in the last fiscal year, and 115 (14%) were closed or withdrawn. During the last 6 months, substantive changes have been made 1) to make the initial review and prioritization of protocols by the CRC and the disease site programs and departments more rigorous, 2) to reduce the time required for review, and 3) to scrutinize accrual more carefully.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-38
Application #
8557388
Study Section
Subcommittee G - Education (NCI)
Project Start
1998-09-04
Project End
2018-06-30
Budget Start
2013-09-06
Budget End
2014-06-30
Support Year
38
Fiscal Year
2013
Total Cost
$325,951
Indirect Cost
$122,271
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Ma, Grace X; Lee, Minsun M; Tan, Yin et al. (2018) Efficacy of a community-based participatory and multilevel intervention to enhance hepatitis B virus screening and vaccination in underserved Korean Americans. Cancer 124:973-982
Peng, Guang; Mills, Gordon B (2018) Surviving Ovarian Cancer: An Affair between Defective DNA Repair and RB1. Clin Cancer Res 24:508-510
Radovich, Milan; Pickering, Curtis R; Felau, Ina et al. (2018) The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell 33:244-258.e10
Tetzlaff, Michael T; Nelson, Kelly C; Diab, Adi et al. (2018) Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer 6:14
Tayob, Nabihah; Richardson, Peter; White, Donna L et al. (2018) Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol 18:1
Caruso, Joseph A; Duong, Mylinh T; Carey, Jason P W et al. (2018) Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res 78:5481-5491
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6

Showing the most recent 10 out of 12418 publications